Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. Efficacy, duration of protection, and percentage of the population receiving the vaccine are key issues
5 Nov, 2020 | 09:09h | UTCChallenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination – The Lancet
Commentary on Twitter
The real deal herd immunity, via a #SARSCoV2 vaccine, will be a formidable feat to achieve, with efficacy, coverage levels and duration of protection as key determinants https://t.co/3jeXkO5Yak @TheLancet pic.twitter.com/mXcDpHbHR6
— Eric Topol (@EricTopol) November 5, 2020